melanotan-2 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-29 and is reviewed periodically as new material appears.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
SVB was a commercial bank founded in 1983 and headquartered in Santa Clara, California. At its collapse, SVB was the 16th largest bank in the U.S. by total assets and was heavily skewed toward serving companies and individuals from the technology industry. Nearly half of U.S. venture capital-backed healthcare and technology companies were financed by SVB. Companies such as Airbnb, Cisco, Fitbit, Pinterest, and Block, Inc. have been clients of the bank. In addition to financing venture-backed companies, SVB was well known as a source of private banking, personal credit lines, and mortgages to tech entrepreneurs, and specialized lending money to higher-risk new companies. Silicon Valley Bank required an exclusive relationship of those borrowing from the bank. Prior to Thursday March 9, 2023, SVB was in "sound financial condition", according to the California Department of Financial Protection and Innovation, though an increased number of short sellers began to target SVB earlier in the year. Employees received their annual bonuses on March 10, 2023, hours before the government took control of the company. As of the last call report of the bank, filed on December 31, 2022, it held $209 billion in total assets, with $175.5 billion in total deposits, of which the bank estimated $151.6 billion (86.4 percent) were uninsured.
== Diagnosis == Protein function tests that demonstrate a reduce in chorein levels and also genetic analysis can confirm the diagnosis given to a patient. For a disease like this it is often necessary to sample the blood of the patient on multiple occasions with a specific request given to the haematologist to examine the film for acanthocytes. Another point is that the diagnosis of the disease can be confirmed by the absence of chorein in the western blot of the erythrocyte membranes.
Viola arvensis is a species of violet known by the common name field pansy. It is native to Europe, western Asia, and North Africa, and it is known on other continents as an introduced species and a weed of disturbed and cultivated areas. Viola arvensis was shown to contain cyclotides, a class of peptides found in plants. The peptide cycloviolacin O2 in particular has shown to possess cytotoxic activity against human cancer cells and is therefore looked at as a potential drug lead.
In the 2021 Census of Population conducted by Statistics Canada, the census districts within the former city had a population of 629,941 living in 218,928 of its 228,939 total private dwellings, a change of −0.3% from its 2016 population of 632,098. With a land area of 187.70 square kilometres (72.47 sq mi), it had a population density of 3,356.1 people/km2 (8,692 people/sq mi) in 2021. The majority of the district's population is between 25 and 64 years old. 52% fell into that "working age" during the last major survey, which also found 21% of Scarborough's population was 14 years old or younger, 15% were between 15 and 24, while senior citizens aged 65+ made up the remaining 12%. Like the rest of Canada, the population is aging. It is projected that close to 30% of Scarborough residents will be senior citizens by 2041. Scarborough has a large number of retirement communities, which attracts more seniors to the area creating a situation where the two largest age demographics in Scarborough will be over 55 and under 25.
Eddy tried every remedy for her ill health, including a three-month stay at the Vail's Hydropathic Institute in Hill, New Hampshire. She told the Boston Post in 1883 that, for the seven years prior to 1862 (most of her second marriage), she had been effectively confined to her bed or room. In 1861 Eddy heard of a healing method developed by Phineas Parkhurst Quimby, a former clockmaker in Portland, Maine. Self-styled Dr. P. P. Quimby, a practitioner of the "Science of Health," had become interested in healing after recovering suddenly from a condition he believed was consumption (tuberculosis). After attending a lecture in Maine in 1837 by the French mesmerist Charles Poyen, Quimby began to practice mesmerism himself. Mesmerism was named after Franz Mesmer (1734–1815), a German physician who argued for the existence of a fluid through which bodies could influence each other, a force he called animal magnetism. Quimby and an assistant, Lucius Burkmar, traveled around Maine and New Brunswick giving demonstrations; Burkmar, in a trance, would offer mind readings and suggestions for cures. Quimby abandoned mesmerism around 1847 when he realized that it was suggestion that was effecting the apparent cures. He came to the view that disease was a mental state. When Jesus healed a paralysed arm, he had known, Quimby wrote, "that the arm was not the cause but the effect, and he addressed Himself to the intelligence, and applied His wisdom to the cause".
Sources: en.wikipedia.org
=== 3. Cementum === In periodontal breakdown associated with attachment loss, previously covered cementum surfaces become exposed to the oral environment. As periodontal ligament fiber insertions are destroyed, cementum loses its functional connective tissue anchorage, leaving the root surface vulnerable and biologically altered.
=== Pharmacokinetics === Following oral administration, sarcosine is absorbed from the gastrointestinal tract. It is metabolised to glycine primarily by SARDH in the mitochondrial matrix and to a lesser extent by PIPOX in peroxisomes.
== History == DOPR was first described in the literature by Alexander Shulgin in 1970. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
In early 2012, prices for cattle futures contracts on the Chicago Mercantile Exchange fell as result of the controversy. Cargill started using a label stating "Contains Finely Textured Beef" from 2014. Production of finely textured beef increased modestly, as beef prices rose by 27% over two years in 2014 and "retailers [sought] cheaper trimmings to include in hamburger meat and processors find new products to put it in". Senior management of Cargill claimed almost full recovery as sales tripled. BPI regained 40 customers that are mostly processors and patty-makers who distribute to retailers and the USDA since March 2012. It does not label its product.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.